Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Oncological Outcomes and Long-Term Survival among Patients with Gastric Cancer and Limited Peritoneal Disease Progression after Neoadjuvant Chemotherapy.
J Clin Med
; 13(1)2023 Dec 27.
Article
em En
| MEDLINE
| ID: mdl-38202168
ABSTRACT
INTRODUCTION:
The role of surgery in stage IV gastric cancer with peritoneal metastasis (PM) remains unclear. The objective of the current single-center study was to define the impact of gastrectomy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on outcomes among Central European GC patients with limited peritoneal disease progression after neoadjuvant chemotherapy (NAC).METHODS:
Patients with histologically confirmed GC who underwent curative-intent multimodal treatment between 2013 and 2023 were included. Patients without adenocarcinoma, who did not undergo gastrectomy, had early (cT1) or metastatic GC at the time of initial diagnosis, who underwent multivisceral resection, incomplete cytoreduction or palliative care, died before planned curative-intent treatment, or had incomplete clinical or pathological missing information were excluded.RESULTS:
A total of 74 patients who underwent curative-intent treatment for GC with PM were included in the final analytic cohort. Patients who underwent gastrectomy with CRS+HIPEC were less likely to achieve TOO (CRS+HIPEC 28% vs. CRS 57.1%, p = 0.033) compared with individuals after CRS alone. Specifically, patients who underwent gastrectomy with CRS+HIPEC had a higher likelihood of postoperative complications (CRS+HIPEC 48% vs. CRS 20.4%, p = 0.018) and longer hospital LOS (median, CRS+HIPEC 12 vs. CRS 10, p = 0.019). While administration of HIPEC did not impact long-term survival (median OS, CRS+HIPEC 16 months vs. CRS 12 months, p = 0.55), postoperative complications (median OS, CCI < 3016 months vs. CCI > 305 months, p = 0.024) and ICU stay (median OS, no ICU stay 16 months vs. ICU stay 5 months, p = 0.008) were associated with worsened long-term survival among GC patients with PM.CONCLUSIONS:
Data from the current study demonstrated a lack of survival benefit among advanced GC patients with PM undergoing gastrectomy with CRS+HIPEC when compared with individuals after gastrectomy with CRS alone. Administration of perioperative chemotherapy and achievement of TO failed to withstand the peritoneal disease progression during NAC.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Clin Med
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Polônia